Prenatal exposure to serotonin reuptake inhibitors and congenital heart anomalies: An exploratory pharmacogenetics study

Aizati N A Daud; Jorieke E H Bergman; Wilhelmina S Kerstjens-Frederikse; Pieter van der Vlies; Eelko Hak; Rolf M F Berger; Henk Groen; Bob Wilffert

doi:10.2217/pgs-2017-0036

Prenatal exposure to serotonin reuptake inhibitors and congenital heart anomalies: An exploratory pharmacogenetics study

Aizati N A Daud, Jorieke E H Bergman, Wilhelmina S Kerstjens-Frederikse, Pieter van der Vlies, Eelko Hak, Rolf M F Berger, Henk Groen, Bob Wilffert

Research output: Contribution to journal › Article › Academic › peer-review

4 Citations (Scopus)

26 Downloads (Pure)

Abstract

Aim: To explore the role of pharmacogenetics in determining the risk of congenital heart anomalies (CHA) with prenatal use of serotonin reuptake inhibitors.

Methods: We included 33 case-mother dyads and 2 mother-only (child deceased) cases of CHA in a case-only study. Ten genes important in determining fetal exposure to serotonin reuptake inhibitors were examined: CYP1A2, CYP2C9, CYP2C19, CYP2D6, ABCB1, SLC6A4, HTR1A, HTR1B, HTR2A and HTR3B.

Results: Among the exposed cases, polymorphisms that tended to be associated with an increased risk of CHA were SLC6A4 5-HTTLPR and 5-HTTVNTR, HTR1A rs1364043, HTR1B rs6296 and rs6298 and HTR3B rs1176744, but none reached statistical significance due to our limited sample sizes.

Conclusion: We identified several polymorphisms that might potentially affect the risk of CHA among exposed fetuses, which warrants further investigation.

Original language	English
Pages (from-to)	987-1001
Number of pages	15
Journal	Pharmacogenomics
Volume	18
Issue number	10
DOIs	https://doi.org/10.2217/pgs-2017-0036
Publication status	Published - 1-Jul-2017

Keywords

gene-environment interaction
heart defects
pharmacogenetics
serotonin reuptake inhibitors
teratogenicity
GENE-ENVIRONMENT INTERACTIONS
ANTIDEPRESSANT THERAPY
P-GLYCOPROTEIN
ABCB1 GENE
PROMOTER POLYMORPHISM
CLINICAL-RESPONSE
MAJOR DEPRESSION
PREGNANT-WOMEN
MEDICATION USE
RISK-FACTORS

Access to Document

10.2217/pgs-2017-0036

Prenatal exposure to serotonin reuptake inhibitors and congenital heart anomaliesFinal publisher's version, 1.24 MBLicence: Taverne

Handle.net

Persistent link

Cite this

@article{a75a3a7c4164450babead2bd33c14bce,

title = "Prenatal exposure to serotonin reuptake inhibitors and congenital heart anomalies: An exploratory pharmacogenetics study",

abstract = "Aim: To explore the role of pharmacogenetics in determining the risk of congenital heart anomalies (CHA) with prenatal use of serotonin reuptake inhibitors. Methods: We included 33 case-mother dyads and 2 mother-only (child deceased) cases of CHA in a case-only study. Ten genes important in determining fetal exposure to serotonin reuptake inhibitors were examined: CYP1A2, CYP2C9, CYP2C19, CYP2D6, ABCB1, SLC6A4, HTR1A, HTR1B, HTR2A and HTR3B. Results: Among the exposed cases, polymorphisms that tended to be associated with an increased risk of CHA were SLC6A4 5-HTTLPR and 5-HTTVNTR, HTR1A rs1364043, HTR1B rs6296 and rs6298 and HTR3B rs1176744, but none reached statistical significance due to our limited sample sizes. Conclusion: We identified several polymorphisms that might potentially affect the risk of CHA among exposed fetuses, which warrants further investigation.",

keywords = "gene-environment interaction, heart defects, pharmacogenetics, serotonin reuptake inhibitors, teratogenicity, GENE-ENVIRONMENT INTERACTIONS, ANTIDEPRESSANT THERAPY, P-GLYCOPROTEIN, ABCB1 GENE, PROMOTER POLYMORPHISM, CLINICAL-RESPONSE, MAJOR DEPRESSION, PREGNANT-WOMEN, MEDICATION USE, RISK-FACTORS",

author = "Daud, {Aizati N A} and Bergman, {Jorieke E H} and Kerstjens-Frederikse, {Wilhelmina S} and {van der Vlies}, Pieter and Eelko Hak and Berger, {Rolf M F} and Henk Groen and Bob Wilffert",

year = "2017",

month = jul,

day = "1",

doi = "10.2217/pgs-2017-0036",

language = "English",

volume = "18",

pages = "987--1001",

journal = "Pharmacogenomics",

issn = "1462-2416",

publisher = "FUTURE MEDICINE LTD",

number = "10",

}

TY - JOUR

T1 - Prenatal exposure to serotonin reuptake inhibitors and congenital heart anomalies

T2 - An exploratory pharmacogenetics study

AU - Daud, Aizati N A

AU - Bergman, Jorieke E H

AU - Kerstjens-Frederikse, Wilhelmina S

AU - van der Vlies, Pieter

AU - Hak, Eelko

AU - Berger, Rolf M F

AU - Groen, Henk

AU - Wilffert, Bob

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Aim: To explore the role of pharmacogenetics in determining the risk of congenital heart anomalies (CHA) with prenatal use of serotonin reuptake inhibitors. Methods: We included 33 case-mother dyads and 2 mother-only (child deceased) cases of CHA in a case-only study. Ten genes important in determining fetal exposure to serotonin reuptake inhibitors were examined: CYP1A2, CYP2C9, CYP2C19, CYP2D6, ABCB1, SLC6A4, HTR1A, HTR1B, HTR2A and HTR3B. Results: Among the exposed cases, polymorphisms that tended to be associated with an increased risk of CHA were SLC6A4 5-HTTLPR and 5-HTTVNTR, HTR1A rs1364043, HTR1B rs6296 and rs6298 and HTR3B rs1176744, but none reached statistical significance due to our limited sample sizes. Conclusion: We identified several polymorphisms that might potentially affect the risk of CHA among exposed fetuses, which warrants further investigation.

AB - Aim: To explore the role of pharmacogenetics in determining the risk of congenital heart anomalies (CHA) with prenatal use of serotonin reuptake inhibitors. Methods: We included 33 case-mother dyads and 2 mother-only (child deceased) cases of CHA in a case-only study. Ten genes important in determining fetal exposure to serotonin reuptake inhibitors were examined: CYP1A2, CYP2C9, CYP2C19, CYP2D6, ABCB1, SLC6A4, HTR1A, HTR1B, HTR2A and HTR3B. Results: Among the exposed cases, polymorphisms that tended to be associated with an increased risk of CHA were SLC6A4 5-HTTLPR and 5-HTTVNTR, HTR1A rs1364043, HTR1B rs6296 and rs6298 and HTR3B rs1176744, but none reached statistical significance due to our limited sample sizes. Conclusion: We identified several polymorphisms that might potentially affect the risk of CHA among exposed fetuses, which warrants further investigation.

KW - gene-environment interaction

KW - heart defects

KW - pharmacogenetics

KW - serotonin reuptake inhibitors

KW - teratogenicity

KW - GENE-ENVIRONMENT INTERACTIONS

KW - ANTIDEPRESSANT THERAPY

KW - P-GLYCOPROTEIN

KW - ABCB1 GENE

KW - PROMOTER POLYMORPHISM

KW - CLINICAL-RESPONSE

KW - MAJOR DEPRESSION

KW - PREGNANT-WOMEN

KW - MEDICATION USE

KW - RISK-FACTORS

U2 - 10.2217/pgs-2017-0036

DO - 10.2217/pgs-2017-0036

M3 - Article

C2 - 28639488

SN - 1462-2416

VL - 18

SP - 987

EP - 1001

JO - Pharmacogenomics

JF - Pharmacogenomics

IS - 10

ER -